Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
187 hedge funds and large institutions have $1.49B invested in Array Biopharma Inc in 2017 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 62 increasing their positions, 61 reducing their positions, and 21 closing their positions.
129% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 21
12% more funds holding
Funds holding: 167 → 187 (+20)
6% more capital invested
Capital invested by funds: $1.41B → $1.49B (+$82.4M)
10% more call options, than puts
Call options by funds: $30.6M | Put options by funds: $27.9M
2% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 61
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$137M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.5M |
| 3 |
Millennium Management
New York
|
+$49.4M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$38.5M |
| 5 |
Two Sigma Investments
New York
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$41M |
| 2 |
Morgan Stanley
New York
|
-$28.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$23.7M |
| 4 |
O
OrbiMed
New York
|
-$20.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
ARRY Hedge Fund Activity: Q1 2017 in Review
187 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2017, worth a combined $1.49B — up 5.9% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ARRY positions and 21 closed out — a net gain of 27 holders — while 62 added to existing stakes and 61 trimmed.
The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Redmile Group, cutting an estimated $41M.
- 187 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2017, up from 167 in Q4 2016.
- Funds reported $1.49B of Array Biopharma Inc stock for Q1 2017, up 5.9% quarter-over-quarter.
- 48 funds opened new Array Biopharma Inc positions in Q1 2017 and 21 closed out, a net change of +27 holders.
- The largest Array Biopharma Inc buyer in Q1 2017 was BlackRock, an estimated $137M added.
- The largest Array Biopharma Inc seller in Q1 2017 was Redmile Group, an estimated $41M sold.
Based on aggregated 13F filings for Q1 2017.